SLC35A2 somatic variants in drug resistant epilepsy: FCD and MOGHE

Area of Science:

• Neuroscience
• Genetics
• Developmental Biology

Background:

• Drug-resistant epilepsy (DRE) in patients with malformations of cortical development (MCD) is often linked to de novo somatic mutations in neuroglial progenitor cells.
• Focal cortical dysplasia type II (FCD II) is associated with somatic variants in mTOR pathway genes, presenting with specific histopathological features.
• The molecular basis of FCD type I (FCD I) remains less understood, lacking the characteristic cytomegalic neurons and balloon cells of FCD II.

Approach:

• This review focuses on somatic mutations in Solute Carrier Family 35 member A2 (SLC35A2) and their role in epilepsy.
• It examines the link between SLC35A2 mutations, FCD type I, and the MOGHE (mild malformation of cortical development with oligodendroglial hyperplasia) phenotype.
• The review synthesizes current knowledge on SLC35A2 biology and its contribution to epilepsy pathogenesis.

Key Points:

• Somatic mutations in SLC35A2 are identified as a cause of DRE associated with FCD I.
• SLC35A2 mutations are also linked to a distinct phenotype, MOGHE, characterized by oligodendroglial hyperplasia and heterotopic neurons.
• Understanding SLC35A2's role provides insights into the pathogenesis of specific cortical malformations and epilepsy.

Conclusions:

• Somatic SLC35A2 mutations represent a significant molecular link between specific cortical malformations and epilepsy.
• Further research into SLC35A2 biology is crucial for understanding epilepsy pathogenesis and developing targeted therapies.
• These findings highlight the importance of investigating somatic mutations in neurodevelopmental disorders.